IONS - Ionis Pharmaceuticals Inc. (IONS) Q4 2023 Earnings Call Transcript

2024-02-21 16:47:06 ET

Ionis Pharmaceuticals, Inc. (IONS)

Q4 2023 Earnings Conference Call

February 21, 2024 11:30 ET

Company Participants

Wade Walke - Senior Vice President, Investor Relations

Brett Monia - Chief Executive Officer

Richard Geary - Chief Development Officer

Beth Hougen - Chief Financial Officer

Eric Swayze - Executive Vice President, Research

Eugene Schneider - Clinical Chief Clinical Development Officer

Onaiza Cadoret - Chief Global Product Strategy and Operations Officer

Conference Call Participants

Jason Gerberry - BofA

Jessica Fye - JPMorgan

Yanan Zhu - Wells Fargo Securities

Sarah Schram - William Blair

Debjit Chattopadhyay - Guggenheim Securities

Mike Ulz - Morgan Stanley

Tommie Reerink - Goldman Sachs

Luca Issi - RBC

David Lebowitz - Citi

Joseph Stringer - Needham & Company

Kostas Biliouris - BMO Capital Markets

Yaron Werber - Cowen

Allison Bratzel - Piper Sandler

Presentation

Operator

Good morning, and welcome to the Ionis Fourth Quarter and Full Year 2023 Financial Results Conference Call. As a reminder, this call is being recorded. At this time, I would like to turn the call over to Wade Walke, Senior Vice President of Investor Relations to lead off the call. Please begin.

Wade Walke

Thank you, Megan. Before we begin, I encourage everyone to go to the Investors section of the Ionis website to view the press release and related financial tables we will be discussing today, including a reconciliation of GAAP to non-GAAP financials. We believe non-GAAP financial results better represent the economics of our business and how we manage our business. We’ve also posted slides on our website that accompany today’s call.

With me this morning are Brett Monia, Chief Executive Officer; Richard Geary, Chief Development Officer; and Beth Hougen, our Chief Financial Officer. Eric Swayze, our Executive Vice President of Research; Eugene Schneider, Clinical Chief Clinical Development Officer; and Onaiza Cadoret, Chief Global Product Strategy and Operations Officer, will also join us for the Q&A portion of the call.

I would like to draw your attention to Slide 3, which contains our forward-looking language statement. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional detail.

With that, I’ll turn the call over to Brett.

Brett Monia

Thanks Wade. Good morning, everybody, and thanks for joining us today. At Ionis, we are proud of our scientific heritage. We have united groundbreaking science and technology with a relentless passion to discover and develop new transformational medicines. And now that we have validated the broad applicability of our RNA-targeting platform, we’re on the brink of independently delivering our medicines directly to patients. Over the next several years, we expect to successfully launch multiple medicines on our own, while continuing to expand our technology so that we can address the needs of even more patients....

For further details see: